Scientific Interchange & Workshop

On March 8, 2025, a select group of experts in breast cancer (BC) participated in a live workshop to discuss the place of oral selective estrogen receptor degraders (SERDs) in treating hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic BC (MBC). Moderated by Hope S. Rugo, MD, the discussion included the role of oral SERDs as monotherapy or in combination, the optimal integration of SERDs into standard-of-care therapies, and practical approaches including biomarker testing and toxicity management.

On February 13, 2025, a select group of experts in chronic lymphocytic leukemia (CLL) participated in a virtual workshop to discuss the evolving treatment landscape of CLL and discussed subjects ranging from treatment of newly diagnosed patients to therapies for those relapsed/refractory (R/R) disease. Moderated by Alexey V. Danilov, MD, PhD, the discussion covered insights into emerging treatment approaches, novel therapeutic strategies, and sequencing of available therapies to optimize patient outcomes.

Disease Mechanisms, Diagnostic Challenges, and Multidisciplinary Treatment Strategies

This article was sponsored by PharmaEssentia.